Mitigation of radiation injuries via suppression of the renin-angiotensin system: emphasis on radiation nephropathy. Curr Drug Targets 2010 Nov;11(11):1423-9
Date
06/30/2010Pubmed ID
20583975Pubmed Central ID
PMC3814179DOI
10.2174/1389450111009011423Scopus ID
2-s2.0-78649985989 (requires institutional sign-in at Scopus site) 35 CitationsAbstract
Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
Author List
Cohen EP, Fish BL, Moulder JEMESH terms used to index this publication - Major topics in bold
Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme Inhibitors
Animals
Humans
Kidney
Kidney Diseases
Radiation Injuries
Renin-Angiotensin System
